UY34381A - Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes - Google Patents
Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunesInfo
- Publication number
- UY34381A UY34381A UY0001034381A UY34381A UY34381A UY 34381 A UY34381 A UY 34381A UY 0001034381 A UY0001034381 A UY 0001034381A UY 34381 A UY34381 A UY 34381A UY 34381 A UY34381 A UY 34381A
- Authority
- UY
- Uruguay
- Prior art keywords
- immune
- autoimmune diseases
- treat cancer
- inductive agents
- apoptosis
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547165P | 2011-10-14 | 2011-10-14 | |
| CN2012078372 | 2012-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY34381A true UY34381A (es) | 2013-05-31 |
Family
ID=47073545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001034381A UY34381A (es) | 2011-10-14 | 2012-10-10 | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP3266776A1 (enExample) |
| JP (2) | JP6049738B2 (enExample) |
| KR (1) | KR102056587B1 (enExample) |
| CN (1) | CN109535155B (enExample) |
| AR (1) | AR088328A1 (enExample) |
| AU (2) | AU2012322818A1 (enExample) |
| BR (1) | BR112014009052B1 (enExample) |
| CA (1) | CA2850976C (enExample) |
| CL (1) | CL2014000922A1 (enExample) |
| CO (1) | CO6950477A2 (enExample) |
| DO (1) | DOP2014000074A (enExample) |
| EC (1) | ECSP14000606A (enExample) |
| ES (1) | ES2699966T3 (enExample) |
| IL (1) | IL231926A (enExample) |
| MX (2) | MX364950B (enExample) |
| PE (2) | PE20181357A1 (enExample) |
| PH (1) | PH12014500815B1 (enExample) |
| RU (1) | RU2594282C2 (enExample) |
| SG (2) | SG11201401479SA (enExample) |
| TW (1) | TWI561521B (enExample) |
| UY (1) | UY34381A (enExample) |
| WO (1) | WO2013055895A1 (enExample) |
| ZA (1) | ZA201402555B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| CN103987711B (zh) | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
| BR112017012342A2 (pt) * | 2014-12-09 | 2018-02-27 | Abbvie Inc | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos |
| WO2016131100A1 (en) * | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| EP3952853A4 (en) * | 2019-04-12 | 2023-04-12 | Tonix Pharmaceuticals Holding Corp. | INHIBITORS OF CD40-CD154 BINDING |
| KR102316961B1 (ko) * | 2020-01-29 | 2021-10-26 | 프라비바이오 주식회사 | 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물 |
| CN116761635A (zh) | 2020-11-24 | 2023-09-15 | 诺华股份有限公司 | Bcl-xl抑制剂抗体药物缀合物及其使用方法 |
| CN117794929A (zh) | 2021-02-02 | 2024-03-29 | 法国施维雅药厂 | 选择性bcl-xl protac化合物及使用方法 |
| KR20250027285A (ko) | 2022-05-20 | 2025-02-25 | 노파르티스 아게 | 항신생물 화합물의 항체-약물 접합체 및 그의 사용 방법 |
| CA3255993A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | BCL-XL ANTIBODY-DRUG CONJUGATES AND ASSOCIATED METHODS OF USE |
| CA3256012A1 (en) | 2022-05-20 | 2023-11-23 | Les Laboratoires Servier | ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| TW202540186A (zh) | 2023-11-22 | 2025-10-16 | 瑞士商諾華公司 | 抗ｃｄ７抗體藥物結合物及其使用方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| EP1019385B1 (en) | 1995-09-15 | 2004-01-14 | PHARMACIA & UPJOHN COMPANY | Aminoaryl oxazolidinone n-oxides |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| DE602004009344T2 (de) | 2004-04-19 | 2008-07-10 | Symed Labs Ltd., Hyderabad | Neues verfahren zur herstellung von linezolid und verwandten verbindungen |
| UA91341C2 (ru) * | 2004-07-15 | 2010-07-26 | Амр Текнолоджи, Інк. | Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина |
| US7429661B2 (en) | 2004-07-20 | 2008-09-30 | Symed Labs Limited | Intermediates for linezolid and related compounds |
| WO2006039164A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Novel cyclosporin analogues and their pharmaceutical uses |
| US7297700B2 (en) * | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| BRPI0810362A2 (pt) | 2007-04-19 | 2014-10-29 | Concert Pharmaceuticals Inc | Compostos de morfolinila deuterados |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| JP2010540635A (ja) | 2007-10-02 | 2010-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | ピリミジンジオン誘導体 |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| WO2009051782A1 (en) | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090131363A1 (en) | 2007-10-26 | 2009-05-21 | Harbeson Scott L | Deuterated darunavir |
| CA2747170C (en) * | 2008-12-19 | 2017-07-18 | Abbott Laboratories | Tetrahydroisoquinoline derivatives and their uses to treat cancers and autoimmune disorders |
| CR20110389A (es) * | 2008-12-19 | 2011-07-13 | Abbott Lab | Compuestos y métodos de uso |
| KR20110123657A (ko) * | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
-
2012
- 2012-10-08 TW TW101137132A patent/TWI561521B/zh not_active IP Right Cessation
- 2012-10-10 UY UY0001034381A patent/UY34381A/es unknown
- 2012-10-11 EP EP17185702.2A patent/EP3266776A1/en not_active Withdrawn
- 2012-10-11 MX MX2017014059A patent/MX364950B/es unknown
- 2012-10-11 AU AU2012322818A patent/AU2012322818A1/en not_active Abandoned
- 2012-10-11 WO PCT/US2012/059717 patent/WO2013055895A1/en not_active Ceased
- 2012-10-11 CA CA2850976A patent/CA2850976C/en active Active
- 2012-10-11 EP EP12778012.0A patent/EP2768830B1/en active Active
- 2012-10-11 KR KR1020147012847A patent/KR102056587B1/ko not_active Expired - Fee Related
- 2012-10-11 RU RU2014119254/04A patent/RU2594282C2/ru active
- 2012-10-11 JP JP2014535867A patent/JP6049738B2/ja not_active Expired - Fee Related
- 2012-10-11 PE PE2018001273A patent/PE20181357A1/es unknown
- 2012-10-11 PE PE2014000520A patent/PE20141997A1/es active IP Right Grant
- 2012-10-11 SG SG11201401479SA patent/SG11201401479SA/en unknown
- 2012-10-11 SG SG10201606031XA patent/SG10201606031XA/en unknown
- 2012-10-11 MX MX2014004561A patent/MX351970B/es active IP Right Grant
- 2012-10-11 PH PH1/2014/500815A patent/PH12014500815B1/en unknown
- 2012-10-11 BR BR112014009052-1A patent/BR112014009052B1/pt not_active IP Right Cessation
- 2012-10-11 CN CN201910042347.5A patent/CN109535155B/zh not_active Expired - Fee Related
- 2012-10-11 ES ES12778012T patent/ES2699966T3/es active Active
- 2012-10-12 AR ARP120103812A patent/AR088328A1/es not_active Application Discontinuation
-
2014
- 2014-04-03 IL IL231926A patent/IL231926A/en active IP Right Grant
- 2014-04-08 ZA ZA201402555A patent/ZA201402555B/en unknown
- 2014-04-11 CL CL2014000922A patent/CL2014000922A1/es unknown
- 2014-04-11 DO DO2014000074A patent/DOP2014000074A/es unknown
- 2014-05-07 CO CO14097119A patent/CO6950477A2/es unknown
- 2014-05-13 EC ECIEPI2014606A patent/ECSP14000606A/es unknown
-
2016
- 2016-11-22 JP JP2016226799A patent/JP6337068B2/ja active Active
-
2017
- 2017-07-17 AU AU2017206149A patent/AU2017206149B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34381A (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| CR20140226A (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| UY34382A (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| GT201500248A (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
| GT201200314A (es) | Agentes inductores de apoptosis para el tratamiento de cáncer y de enfermedades inmunes y autoinmunes | |
| MX372754B (es) | Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer. | |
| PE20151604A1 (es) | Terapia adyuvante con inhibidores de quinasa de la familia tec | |
| UY34782A (es) | Anticuerpos humanos para fel d1 y métodos para usarlos. | |
| UY34683A (es) | Esteviol glucosiltransferasas y genes que las codifican | |
| DOP2016000100A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| UY34726A (es) | Proceso de montaje de tanques y dispositivos para realizarlo | |
| AR089993A1 (es) | Macrociclos peptidomimeticos | |
| SMT201600016B (it) | Agenti di induzione di apoptosi per il trattamento del cancro e di malattie immuni e autoimmuni | |
| MX2015003140A (es) | Formulaciones de enzalutamida. | |
| GT201400147A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
| MX391858B (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| MX2019009437A (es) | Tratamiento de mielosupresion. | |
| CL2016000392A1 (es) | Análogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune | |
| UY33884A (es) | Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes | |
| CL2015002724A1 (es) | Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23 | |
| CR20140573A (es) | Inhibidores del nampt | |
| CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares | |
| UY34078A (es) | Composiciones farmacéuticas y métodos para tratar el cáncer | |
| UY34124A (es) | Cerramiento y método para conformarlo |